79 使用 filgrastim（Neupogen）預防癌症化療（chemotherapy）引起之 neutropenia 時，其給藥時機為：
(A)化療開始前 24 小時內
(B)化療進行中任何時間
(C)化療最後一個劑量後 24 小時
(D)與化療同步

仿單建議:

化療(第二天後)

劑量用法:

5 mcg/kg/day as a single daily subcutaneous bolus injection, or short IV infusion (15 to 30 minutes), or by continuous IV infusion; doses may be increased by 5 mcg/kg for each chemotherapy cycle according to the duration and severity of the absolute neutrophil count (ANC) nadir; stop therapy if the ANC increases beyond 10,000/mm3

Duration of therapy: Up to 2 weeks or until the ANC has reached 10,000/mm3 following the expected chemotherapy-induced neutrophil nadir (a transient increase in neutrophil count is typically seen 1 to 2 days after initiation of therapy)

Comments:

-A CBC and platelet count should be obtained before instituting therapy and monitored twice weekly during therapy.

-Do not administer this drug during the period 24 hours before or 24 hours after the administration of cytotoxic chemotherapy.

-The duration of therapy needed to attenuate chemotherapy-induced neutropenia may be dependent on the myelosuppressive potential of the chemotherapy regimen used.